A randomised double-blind, placebo-controlled trial of magnesium in patients with paroxysmal lone atrial fibrillation.

Phase 3

Recruiting

• Conditions: paroxysmal lone atrial fibrillation; Cardiovascular - Coronary heart disease

• Registration Number: ACTRN12610000181000
• Lead Sponsor: euroscience Department, Barwon Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-03-01
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Patients with paroxysmal lone atrial fibrillation documented by an electrical tracing (minimum of 2 episodes within prior 12 months)

Exclusion Criteria

1.Renal Failure with a serum urea > 10 mmol/L.
2.Untreated hyperthyroidism.
3.Atrial fibrillation with associated cardiac disease with an abnormal transthoracic echocardiogram; e.g. cardiomyopathy, enlarged left atrium, valvular heart disease.
4.Symptomatic Inflammatory Bowel disease.
5.Currently taking Magnesium supplementation.
6.Daily consumption of alcohol >4 standard drinks.
7.Transient paroxysmal atrial fibrillation secondary to other reversible disorders (e.g., thyrotoxicosis, cardiac or thoracic surgery, pneumonia, severe anemia)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of atrial fibrillation confirmed by electrocardiogram or Holter monitor.[1 year following randomisation.];Incidence of symptomatic atrial fibrillation detected by the patient, where an ECG was not possible.[1 year following randomisation.]

Secondary Outcome Measures

Name	Time	Method
nil[nil]